MILFORD, Pa., (UPTICK Newswire – January 6, 2016) — Manzo Pharmaceuticals, Inc. (OTCPink:MNZO), today announced that the human study testing the effectiveness of the company’s much anticipated lactose intolerance remedy, Lacto-Freedom™ , has shown promising results thus far.
Being a probiotic, the human testing is not a legal requirement but is being conducted so that the company can state the effectiveness of the product in certain terms.
For those suffering from lactose intolerance, Lacto-Freedom™ is one of the most exciting probiotic developments in recent years. A single 7 Day treatment of Lacto-Freedom™ could reduce or prevent all lactose intolerance symptoms for months. The success of the preliminary study determined the feasibility of conducting a more formal study, more qualitative and quantitative study paired with a ‘test marketing’ program to the retail market.
The study, originally started in October, was to last 2 months. Due to its success, the company conducting the study, Celprogen, will be adding additional participants.
This study will be conducted with a larger participant base, to acquire more qualitative and quantitative data, and it will be paired with a ‘test market’ to the retail market.
To fund the study and ‘test marketing‘ to the retail market, the Company requires substantially more funding. Manzo Pharmaceuticals Inc. and has undertaken a private placement offer under Regulation D #506 C. The Convertible Notes and concurrent Common Share offer is listed on the FINRA regulated funding portal: directprivateoffers.com
About Manzo Pharmaceuticals, Inc.
Manzo Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in the research, development, and testing of patented and non-patented solutions and remedies. Most notably is a patented solution for lactose Intolerance, and a natural remedy for colic in babies. For more information follow the company on twitter at @manzopharma, and visit www.manzopharma.com.
This Press Release may contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The Company has tried, whenever possible, to identify these forward-looking statements using words such as “anticipates,” “believes,” “estimates,” “expects,” “plans,” “intends,” “potential” and similar expressions. These statements reflect the Company’s current beliefs and are based upon information currently available to it. Accordingly, such forward-looking statements involve known and unknown risks, uncertainties and other factors which could cause the Company’s actual results, performance or achievements to differ materially from those expressed in or implied by such statements. The Company undertakes no obligation to update or advise in the event of any change, addition or alteration to the information catered in this Press Release including such forward-looking statements.